Q-omics provides the consensus-scored MIR3158-1 profile across patient tissues and cancer cell-line models. MIR3158-1 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR3158-1 is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, MIR3158-1 RNA expression shows 5,527 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight UCS, LUSC, and KIRC as cancer lineages where MIR3158-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3158-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3158-1 survival associations across molecular data types. MIR3158-1 RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3158-1 RNA expression–survival associations across cancer types. High MIR3158-1 expression shows unfavorable associations in UCS, CHOL, LIHC, UVM, LUAD and SARC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for MIR3158-1 RNA expression.
This table summarizes MIR3158-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3158-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3158-1 shows lower tumor expression in LUSC and higher tumor expression in PRAD. The LUSC box plot shows higher MIR3158-1 RNA expression in normal versus tumor tissue (log2 FC = −0.135, t-test p = .006).
This table shows molecular features associated with MIR3158-1 in patient tissues and cancer cell lines. In patient samples, MIR3158-1 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
